Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term antagonists & inhibitors. Found 127 abstracts

no pagination
Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DY, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017 Sep 10;35(26):2993-3001.
de Oliveira JF, Lima TS, Vendramini-Costa DB, de Lacerda Pedrosa SC, Lafayette EA, da Silva RM, de Almeida SM, de Moura RO, Ruiz A, de Carvalho JE, de Lima M. Thiosemicarbazones and 4-thiazolidinones indole-based derivatives: Synthesis, evaluation of antiproliferative activity, cell death mechanisms and topoisomerase inhibition assay. European journal of medicinal chemistry. 2017 Aug 18;136:305-14.
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr;35(10):1112-8.   PMCID: PMC5559878
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07;170(6):1109-1119e10.
Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017 Jul;58:70-6.
Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 Sep 19;34(32):3838-45.
Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Muschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 Apr 28;127(17):2131-43.   PMCID: PMC4850868
Haldane A, Flynn WF, He P, Vijayan RS, Levy RM. Structural propensities of kinase family proteins from a Potts model of residue co-variation. Protein science : a publication of the Protein Society. 2016 Aug;25(8):1378-84.   PMCID: PMC4972195
Huang F, Goyal N, Sullivan K, Hanamshet K, Patel M, Mazina OM, Wang CX, An WF, Spoonamore J, Metkar S, Emmitte KA, Cocklin S, Skorski T, Mazin AV. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic acids research. 2016 May 19;44(9):4189-99.   PMCID: PMC4872086
Ji W, Arnst C, Tipton AR, Bekier ME, Taylor WR, Yen TJ, Liu ST. OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases. PLoS One. 2016 Jan;11(4):e0153518.   PMCID: PMC4833387
Prudnikova TY, Villamar-Cruz O, Rawat SJ, Cai KQ, Chernoff J. Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene. 2016 Apr 28;35(17):2178-85.   PMCID: PMC5125076
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan;22(1):34-43.
Zibelman M, Plimack ER. Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm. Oncology (Williston Park). 2016 Feb;30(2):160-2, 176.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England journal of medicine. 2015 Jan 22;372(4):311-9.   PMCID: 4348009
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015 Oct 22;373(17):1627-39.
Chakraborty AK, Mehra R, Digiovanna MP. Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models. Anticancer research. 2015 Mar;35(3):1243-50.
Di Marcantonio D, Galli D, Carubbi C, Gobbi G, Queirolo V, Martini S, Merighi S, Vaccarezza M, Maffulli N, Sykes SM, Vitale M, Mirandola P. PKCepsilon as a novel promoter of skeletal muscle differentiation and regeneration. Exp Cell Res. 2015 Nov 15;339(1):10-9.
Eidem TM, Lounsbury N, Emery JF, Bulger J, Smith A, Abou-Gharbia M, Childers W, Dunman PM. Small-molecule inhibitors of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing. Antimicrob Agents Chemother. 2015 Apr;59(4):2016-28.   PMCID: PMC4356807
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr;21(7):1566-73.
Gianti E, Carnevale V, DeGrado WF, Klein ML, Fiorin G. Hydrogen-bonded water molecules in the M2 channel of the influenza A virus guide the binding preferences of ammonium-based inhibitors. J Phys Chem B. 2015 Jan 22;119(3):1173-83.   PMCID: PMC4386636
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term antagonists & inhibitors

antagonists & inhibitors Antineoplastic Agents drug therapy Female drug effects metabolism genetics adverse effects Middle Aged therapeutic use pharmacology Male Aged chemistry administration & dosage pathology Adult Monoclonal Antibodies-Humanized Tumor Cell Line 80 and over Aged Cell Proliferation therapy Signal Transduction immunology Protein Kinase Inhibitors Monoclonal Antibodies enzymology physiology Immunotherapy Mice Programmed Cell Death 1 Receptor ErbB-2 Receptor chemically induced Local Neoplasm Recurrence Cisplatin Maximum Tolerated Dose CD274 Antigens Protein Binding Inhibitory Concentration 50 Head and Neck Neoplasms Disease-Free Survival Squamous Cell Carcinoma Apoptosis Treatment Outcome mortality Thermodynamics biosynthesis Ovarian Neoplasms Antitumor Drug Screening Assays analogs & derivatives Molecular Targeted Therapy Oncogene Proteins v-abl analysis Retreatment Cell Survival Cell Cycle Checkpoints Neoplasm Drug Resistance High-Throughput Screening Assays Cell Cycle Immunoconjugates diagnosis Melanoma Proto-Oncogene Proteins c-met pembrolizumab Tamoxifen Pyrimidines apoptosis Xenograft Model Antitumor Assays Tumor Microenvironment Kaplan-Meier Estimate Stem Cell Transplantation Anti-Bacterial Agents BRCA1 Protein kinase Diarrhea Pyrazines Programmed Cell Death 1 Ligand 2 Protein SCID Mice Immune-related adverse events Urologic Neoplasms biomarkers Molecular Dynamics Simulation Lymphoma HeLa Cells Lung Neoplasms Trastuzumab Microbial Sensitivity Tests Janus Kinases Mitogen-Activated Protein Kinase 14 Muscle Development Neoplastic Stem Cells Mutation Estrogen Antagonists trastuzumab (Herceptin) Proto-Oncogene Proteins c-abl Experimental Leukemia Thiourea Immunoenzyme Techniques Potts model Fatigue fulvestrant (Faslodex) Real-Time Polymerase Chain Reaction Chemoradiotherapy Survival Analysis Western Blotting Hypotension Reed-Sternberg Cells conformational preference Hydrogen Bonding Small Interfering RNA Skeletal Muscle Anticancer therapy Molecular Models Breast Neoplasms Hydroxamic Acids Thiosemicarbazones Amino Acid Motifs M Phase Cell Cycle Checkpoints Fallopian Tube Neoplasms Nivolumab Cell Line Small Molecule Libraries Secondary Protein Structure Hmga1 Carcinoma CTLA-4 Antigen Non-Small-Cell Lung Carcinoma Type II DNA Topoisomerases Kinetics Oxidative Stress B7-H1 Antigen Taxoids estrogen receptor (ER) Tumor Biomarkers Water Pyridazines PKCepsilon Topoisomerase inhibition Ribonuclease P Urothelium DNA-Binding Proteins Protein Databases Reverse Transcriptase Polymerase Chain Reaction Imidazoles Ammonium Compounds Structure-Activity Relationship cytology Cultured Cells Transfer RNA Hydrophobic and Hydrophilic Interactions
Last updated on Friday, January 05, 2018